Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
88 studies found for:    Alkermes
Show Display Options
Rank Status Study
21 Completed A Study of ALKS 5461 in Healthy Volunteers
Condition: Pharmacokinetics
Interventions: Drug: ALKS 5461;   Drug: Placebo
22 Completed
Has Results
ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)
Condition: Alcoholism
Interventions: Drug: Medisorb naltrexone 380 mg;   Drug: Oral naltrexone 50 mg
23 Completed
Has Results
ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
Condition: Opiate Dependence
Interventions: Drug: Medisorb naltrexone 75 mg;   Drug: Medisorb naltrexone 150 mg;   Drug: Medisorb naltrexone 300 mg;   Drug: Hydromorphone (10 mg/mL);   Drug: Naloxone Challenge and Oral Naltrexone Tolerability Testing
24 Completed
Has Results
ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults
Condition: Alcoholism
Interventions: Drug: Medisorb naltrexone 190 mg;   Drug: Medisorb naltrexone 380 mg;   Drug: Placebo matching Medisorb naltrexone 190 mg;   Drug: Placebo matching Medisorb naltrexone 380 mg
25 Completed
Has Results
ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Placebo;   Drug: TrIP-2D;   Drug: TrIP-2SS;   Drug: TrIP-2SS + Foradil
26 Enrolling by invitation A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: ALKS 3831
27 Enrolling by invitation A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: ALKS 3831
28 Recruiting A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
Condition: Schizophrenia
Interventions: Drug: ALK3831;   Drug: Olanzapine;   Drug: Placebo
29 Completed An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole Lauroxil
30 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: ALKS 9072;   Drug: Placebo
31 Completed A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
32 Completed A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461;   Drug: Placebo
33 Completed A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study
Condition: Major Depressive Disorder
Interventions: Drug: High Dose ALKS 5461;   Drug: Low Dose ALKS 5461;   Drug: Placebo
34 Completed A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Conditions: Schizophrenia;   Schizoaffective Disorder
Intervention: Drug: Aripiprazole Lauroxil
35 Recruiting A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
Condition: Schizophrenia
Interventions: Drug: ALKS 3831;   Drug: Olanzapine
36 Completed A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder
Intervention: Drug: ALKS 5461
37 Recruiting A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: ALKS 8700;   Drug: Dimethyl Fumarate
38 Completed Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
Condition: Opioid Use Disorder
Interventions: Drug: NTX/BUP;   Drug: NTX/PBO-B;   Drug: PBO-N/PBO-B
39 Completed A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
Condition: Schizophrenia
Interventions: Drug: ALKS 9072, Low dose;   Drug: ALKS 9072, Med dose;   Drug: ALKS 9072, High dose;   Drug: Placebo
40 Completed ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
Condition: Binge Eating Disorder
Interventions: Drug: RDC-0313 (ALKS 33);   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.